<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03535324</url>
  </required_header>
  <id_info>
    <org_study_id>NO-BACT (FIS-ANT-2018-01)</org_study_id>
    <nct_id>NCT03535324</nct_id>
  </id_info>
  <brief_title>Opportunities for Antibiotic Optimisation and Outcomes Improvement in Patients With Negative Blood Culture (NO-BACT)</brief_title>
  <acronym>NO-BACT</acronym>
  <official_title>Opportunities for Antibiotic Optimisation and Outcomes Improvement in Patients With Negative Blood Culture (The NO-BACT Project)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with negative blood cultures represent 85-90 % from all patients with a blood
      culture taken during hospital admissions. This population usually includes an heterogeneous
      group of patients that are admitted because of an infectious diseases or febrile syndrome in
      which performing a blood culture is required. There is scarce evidence about the clinical
      characteristics and the antibiotic treatment given to these patients. This project will be
      developped in two phases with an specific target in each one:

        -  Phase I (a cohort study of patient with blood cultured taken): the investigators aim to
           analyse the clinical and therapeutics characteristics, outcomes and antimicrobial
           stewardship oppotunities in a population of patients with negative blood culture. The
           investigators aim to compare the outcomes and antimicrobial stewardship opportunities
           with those in patients with positive blood culture.

        -  Phase II: The investigators will develop a cluster randomised control trial to evaluate
           the implementation of a targeted antimicrobial stewardship intervention in patients with
           negative blood culture (based on 3rd and 5th day audits). The effect of the intervention
           on the quality of antimicrobial use (duration and de-escalation), long of stay and
           mortality will be analysed.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days of treatment (DDT)</measure>
    <time_frame>It will be variable because each individual can have a different treatment days that will vary based on our previous experience between 2 and 28 days . They will be measured only once for each case included.</time_frame>
    <description>Days of treatment per negative hemoculture episode evaluated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Defined Daily Doses (DDDS)</measure>
    <time_frame>Weekly from date of randomization up to 28 days</time_frame>
    <description>Defined Daily Doses of antibiotic used in each episode</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>From 4 to 30 days since only those patients with active antibiotherapy are included at 48 hours and with no death forecast before 48-72 hours after inclusion</time_frame>
    <description>Mortality at 30 days after the extraction of the blood culture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-hospitalization in the next 90 days</measure>
    <time_frame>From 4 to 90 days</time_frame>
    <description>Re-hospitalization in the next 90 days after the extraction of the blood culture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Superinfection by multiresistant microorganisms</measure>
    <time_frame>In the first three months after the negative blood culture</time_frame>
    <description>Rate of reinfection by MDR (multidrug-resistant) bacteria (according to Magiorakos AP et al criteria - International standard definitions for acquired resistance, Clin Microbiol Infect, 2011) among the intervention group patients comparing to rate in the control group patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clostridium difficile diarrhea</measure>
    <time_frame>In the first three months after the negative blood culture</time_frame>
    <description>Rate of patients presenting confirmed Clostridium difficile (CD) diarrhea among the intervention group patients comparing to rate of CD diarrhea about control group patients.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Antibiotic Resistant Infection</condition>
  <arm_group>
    <arm_group_label>PROA for optimization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Development of a Program for optimizing the use of antibiotics (PROA) in Spanish (Antimicrobial Stewardship Program, ASP, in English), based on Reinforcement, Guidance and Support Programs, to prescribing physicians for the optimization of antimicrobial use based on a non-tax counseling program and evidence-based recommendations. The intervention will be carried out at the cluster level (group of patients belonging to a specific hospital service that meet the inclusion criteria). The intervention will consist in carrying out the audit with recommendation on days 3 and 5-7 after the extraction of negative blood cultures to assess the possibilities of de-escalation, sequential oral therapy and end of early treatment based on the available evidence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>There will be no intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>PROA for optimization</intervention_name>
    <description>The development of a ASP based on Reinforcement, Guidance and Support Programs, to prescribing physicians for the optimization of antimicrobial use based on a non-tax counseling program and evidence-based recommendations.</description>
    <arm_group_label>PROA for optimization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>There will be no intervention</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Health professionals in charge of patients with negative hemoculture and active
             antibiotherapy within 48 hours of extraction; and that belong to a clinical unit that
             has been assigned to the intervention arm.

        Exclusion Criteria:

          -  Health professionals in charge of patients who, even if they meet the criteria
             described above, will not be considered to have a foreseeable death within &lt;72hrs from
             the hemoculture extraction or a positive hemoculture in the seven days prior to the
             extraction of the negative hemoculture.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pilar Retamar Gentil, MD/PhD</last_name>
    <role>Study Director</role>
    <affiliation>Virgen Macarena Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pilar Retamar Gentil, MD/PhD</last_name>
    <phone>0034 609517133</phone>
    <email>pilaretamar@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clara M Rosso Fernández, MD/PhD</last_name>
    <phone>0034 955012144</phone>
    <email>claram.rosso.sspa@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Puerta del Mar Hospital</name>
      <address>
        <city>Cadiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francisca M Guerrero Sánchez</last_name>
    </contact>
    <investigator>
      <last_name>Montserrat M de Oca Arjona</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fátima Galán Sánchez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María E Rodríguez Mateos</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José A Giron Gonzalez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virgen Macarena Hospital</name>
      <address>
        <city>Seville</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clara M. Rosso Fernández, MD, PhD</last_name>
      <phone>0034 955 01 21 44</phone>
      <email>claram.rosso.sspa@juntadeandalucia.es</email>
    </contact>
    <contact_backup>
      <last_name>Pilar Retamar Gentil, MD, PhD</last_name>
      <phone>0034 609517133</phone>
      <email>pilaretamar@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Pilar Retamar Gentil, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>José A Girón</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zaira Palacios</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marina de Cueto</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margarita Beltrán</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luisa Cantón</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Jiménez-Jorge, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisca M Guerrero Sánchez</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Montserrat Montes de Oca Arjona</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fátima Galán Sánchez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María E Rodríguez Mateos</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José A Girón González</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pilar Luque</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>María A Allende</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco J Ruiz</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lozano Blesa Hospital</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pilar Luque</last_name>
    </contact>
    <investigator>
      <last_name>María A Allende</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco J Ruiz</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2018</study_first_submitted>
  <study_first_submitted_qc>May 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2018</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

